menu
    • menu

    Company profile for Elevar Therapeutics

    NEW Drugs in Dev: 8
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Elevar Therapeutics is a privately-held pharmaceutical company based in Salt Lake City, Utah with offices in South San Francisco (and Pangyo, South Korea). Elevar Therapeutics specializes in clinical development of promising therapies for unmet medical needs in cancer. Elevar Therapeutics is developing two proprietary drug candidates; rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a var...
    Elevar Therapeutics is a privately-held pharmaceutical company based in Salt Lake City, Utah with offices in South San Francisco (and Pangyo, South Korea). Elevar Therapeutics specializes in clinical development of promising therapies for unmet medical needs in cancer. Elevar Therapeutics is developing two proprietary drug candidates; rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a BTK/JAK3 inhibitor with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent. Elevar Therapeutics holds worldwide rights for rivoceranib exclud

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Elevar TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    400 Oyster Point Blvd, Suite 214 South San Francisco, CA 94080 U.S.A.
    Telephone
    Telephone
    353-1-969-6739
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://elevartherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/elevartherapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Paris Packaging Week

    Paris Packaging Week

    Not Confirmed

    envelop Contact Supplier

    Paris Packaging Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Elevar Pharma Resubmits Rivoceranib-Camrelizumab Combo NDA
    Elevar Pharma Resubmits Rivoceranib-Camrelizumab Combo NDA

    30 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/30/3229623/0/en/Elevar-Therapeutics-Announces-FDA-Acceptance-of-New-Drug-Application-Resubmission-for-Rivoceranib-in-Combination-with-Camrelizumab-as-a-First-line-Systemic-Treatment-for-Unresectab.html

    GLOBENEWSWIRE
    30 Jan 2026
    Share Share
    Elevar Therapeutics Names Dong-Gun Kim CEO for Post-NDA Push
    Elevar Therapeutics Names Dong-Gun Kim CEO for Post-NDA Push

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3228675/0/en/Elevar-Therapeutics-Names-Dong-Gun-Kim-CEO-as-It-Focuses-on-Post-NDA-Commercialization-Strategy.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    Elevar Pharma Seeks FDA Approval For Lirafugratinib
    Elevar Pharma Seeks FDA Approval For Lirafugratinib

    28 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/28/3228106/0/en/Elevar-Therapeutics-Submits-New-Drug-Application-to-FDA-for-Lirafugratinib-as-Second-Line-Treatment-Option-for-Cholangiocarcinoma.html

    GLOBENEWSWIRE
    28 Jan 2026
    Share Share
    Elevar Therapeutics Publishes CARES-310 Study Final Analysis
    Elevar Therapeutics Publishes CARES-310 Study Final Analysis

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3199018/0/en/Elevar-Therapeutics-Announces-Publication-of-CARES-310-Study-Final-Analysis-in-The-Lancet-Oncology.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    FDA rejects Hengrui, Elevar's PD-1 cancer drug combo—again
    FDA rejects Hengrui, Elevar's PD-1 cancer drug combo—again

    22 Mar 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/fda-rejects-hengrui-elevars-pd-1-cancer-drug-combination-again

    FIERCE PHARMA
    22 Mar 2025
    Share Share
    Elevar Therapeutics Announce Formation & Members of Advisory Board
    Elevar Therapeutics Announce Formation & Members of Advisory Board

    27 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/27/3015867/0/en/Elevar-Therapeutics-Announces-the-Formation-and-Members-of-Scientific-Advisory-Board.html

    GLOBENEWSWIRE
    27 Jan 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search